Penpulimab vs Sasanlimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Penpulimab

Marketed by Akeso and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT03866993 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled Phase 3 trial in 350 patients with advanced squamous non-small-cell lung cancer, all of whom also received paclitaxel and carboplatin. An independent radiology committee assessed progression-free survival in two primary populations: all randomized patients and the PD-L1-positive subgroup. Penpulimab improved progression-free survival in both populations (median 7.6 vs 4.2 months overall and 8.1 vs 4.2 months in PD-L1-positive patients, both p<0.0001), so the trial met its primary endpoint. The figures come from the peer-reviewed Lancet Respiratory Medicine paper.

Reported efficacy

Progression-free survival (PFS) in intent-to-treat (ITT) population, assessed by Independent Radiologist Review Committee(IRRC) in accordance with RECIST v1.1 (Up to approximately 2 years); PFS in PD-L1-selected population, assessed by IRRC in accordance with RECIST v1.1 (Up to approximately 2 years): Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met. (met)

Result source: NCT03866993

Sasanlimab

Developed by Pfizer

Phase 2/3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT04181788 · Phase 1/2 · completed

Phase 1/2 open-label study in advanced malignancies (155 participants). The primary endpoints are dose-limiting toxicities and pharmacokinetic exposure, reported descriptively; no efficacy hypothesis was tested as a primary comparison.

Reported efficacy

Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) (Phase 1b: at the end of cycle 1 (28 days) for the PF-06801591 300 mg SC Q4W arms, and (42 days) for the PF-06801591 600 mg SC Q6W arms); Phase 2: AUCτ of PF-06801591 at Steady State (Phase 2: Cycle 4 Day 1, 8, 15, 22 and Cycle 5 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1, 8, 15, 29 and Cycle 4 Day 1 for the PF-06801591 600 mg SC Q6W arm); Phase 2: Ctrough of PF-06801591 at Steady State, at Week 12 (Phase 2: Cycle 4 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1 for the PF-06801591 600 mg SC Q6W arm): Dose-limiting toxicities in phase 1b: 0 participants in each of the four arms (sasanlimab 300 mg SC Q4W escalation and expansion, 600 mg SC Q6W escalation and expansion); no comparator arm. (not_applicable)

Result source: NCT04181788

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPenpulimabSasanlimab
PFS, median8.6 vs 4.2a+4.4 vs placeboNCT03866993—Trial running · NCT06218069
OS, median—Not posted · NCT0386699314.7b300 mg SC · n 68NCT02573259
1 other result
  • 10.9 300 mg SC · n 39 · Phase 1 · secondary NCT02573259
ORR—Not posted · NCT0386699316.4%b300 mg SC · n 67NCT02573259
3 other results
  • 18.4% 300 mg SC · n 38 · Phase 1 · primary NCT02573259
  • 19.4% 300 mg SC · n 67 · Phase 1 · primary NCT02573259
  • 21.1% 300 mg SC · n 38 · Phase 1 · primary NCT02573259
Duration of response, median—Not posted · NCT03866993—Trial running · NCT06218069

PFS, median

Penpulimab
8.6 vs 4.2a+4.4 vs placeboNCT03866993
Sasanlimab
—Trial running · NCT06218069

OS, median

Penpulimab
—Not posted · NCT03866993
Sasanlimab
14.7b300 mg SC · n 68NCT02573259
1 other result
  • 10.9 300 mg SC · n 39 · Phase 1 · secondary NCT02573259

ORR

Penpulimab
—Not posted · NCT03866993
Sasanlimab
16.4%b300 mg SC · n 67NCT02573259
3 other results
  • 18.4% 300 mg SC · n 38 · Phase 1 · primary NCT02573259
  • 19.4% 300 mg SC · n 67 · Phase 1 · primary NCT02573259
  • 21.1% 300 mg SC · n 38 · Phase 1 · primary NCT02573259

Duration of response, median

Penpulimab
—Not posted · NCT03866993
Sasanlimab
—Trial running · NCT06218069
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  3. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  4. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Penpulimab: 0 of 4 rows · Sasanlimab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPenpulimabSasanlimab
Dropout rate—
n/a: no completion milestone600 mg SC Q6Wa
NCT04181788 · Phase 1/2
show 12 more results
n/a: no completion milestone600 mg SC Q6W
NCT04181788 · Phase 1/2
n/a: no completion milestone600 mg SC Q6W
NCT04181788 · Phase 1/2
n/a: no completion milestone300 mg SC Q4W
NCT04181788 · Phase 1/2
n/a: no completion milestone300 mg SC Q4W
NCT04181788 · Phase 1/2
n/a: no completion milestone300 mg SC Q4W
NCT04181788 · Phase 1/2
86.7%300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
85.3%300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
87.2%300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
85.7%10 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
75%3 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
100%1 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
50%0.5 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs—
16.7%600 mg SC Q6Wa
NCT04181788 · Phase 1/2
show 12 more results
0%600 mg SC Q6W
NCT04181788 · Phase 1/2
3.8%600 mg SC Q6W
NCT04181788 · Phase 1/2
0%300 mg SC Q4W
NCT04181788 · Phase 1/2
16.7%300 mg SC Q4W
NCT04181788 · Phase 1/2
2.4%300 mg SC Q4W
NCT04181788 · Phase 1/2
—300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
—300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
—300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
—10 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
—3 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
—1 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
—0.5 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
Serious AEs—
0%600 mg SC Q6Wa
NCT04181788 · Phase 1/2
show 12 more results
0%600 mg SC Q6W
NCT04181788 · Phase 1/2
16.3%600 mg SC Q6W
NCT04181788 · Phase 1/2
25%300 mg SC Q4W
NCT04181788 · Phase 1/2
16.7%300 mg SC Q4W
NCT04181788 · Phase 1/2
39%300 mg SC Q4W
NCT04181788 · Phase 1/2
20%300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
26.5%300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
34.2%300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
42.9%10 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
37.5%3 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
37.5%1 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
50%0.5 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs—
600 mg SC Q6Wa
pruritus 50%
alanine aminotransferase increased 16.7%
alopecia 16.7%
NCT04181788 · Phase 1/2
show 12 more results
600 mg SC Q6W
anaemia 50%
blood glucose increased 33.3%
blood bilirubin increased 25%
NCT04181788 · Phase 1/2
600 mg SC Q6W
dyspnoea 13.8%
anaemia 12.5%
weight decreased 12.5%
NCT04181788 · Phase 1/2
300 mg SC Q4W
alanine aminotransferase increased 25%
anaemia 25%
aspartate aminotransferase increased 25%
NCT04181788 · Phase 1/2
300 mg SC Q4W
anaemia 33.3%
hypertriglyceridaemia 33.3%
hypoalbuminaemia 33.3%
NCT04181788 · Phase 1/2
300 mg SC Q4W
asthenia 22%
dyspnoea 22%
anaemia 19.5%
NCT04181788 · Phase 1/2
300 mg SC
decreased appetite 46.7%
nausea 40%
dyspnoea 33.3%
NCT02573259 · Phase 1 · registry result, not featured evidence
300 mg SC
anaemia 19.1%
dyspnoea 14.7%
decreased appetite 13.2%
NCT02573259 · Phase 1 · registry result, not featured evidence
300 mg SC
anaemia 31.6%
asthenia 15.8%
back pain 15.8%
NCT02573259 · Phase 1 · registry result, not featured evidence
10 mg/kg IV
generalised oedema 57.1%
constipation 42.9%
aspartate aminotransferase increased 28.6%
NCT02573259 · Phase 1 · registry result, not featured evidence
3 mg/kg IV
generalised oedema 50%
arthralgia 37.5%
blood thyroid stimulating hormone increased 37.5%
NCT02573259 · Phase 1 · registry result, not featured evidence
1 mg/kg IV
constipation 50%
decreased appetite 37.5%
generalised oedema 37.5%
NCT02573259 · Phase 1 · registry result, not featured evidence
0.5 mg/kg IV
back pain 100%
blood creatinine increased 100%
constipation 100%
NCT02573259 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Penpulimab

PFS 8.6 vs 4.2 placebo months
time to event · months
NCT03866993 · Phase 3 · sponsor-reported, not registry data

Sasanlimab

ORR 16.4% (n=67)300 mg SC
responder rate · % of participants
No placebo or comparator arm
NCT02573259 · Phase 1 · registry result, not featured evidence
show 3 more results
18.4% (n=38)300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
19.4% (n=67)300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
21.1% (n=38)300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
ORR 6.7% (n=15)300 mg SC
event count · % of participants
No placebo or comparator arm
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 1 Participants as posted
show 9 more results
6.7% (n=15)*300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 1 Participants as posted
28.6% (n=7)*10 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 2 Participants as posted
28.6% (n=7)*10 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 2 Participants as posted
12.5% (n=8)*3 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 1 Participants as posted
12.5% (n=8)*3 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 1 Participants as posted
28.6% (n=7)*1 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 2 Participants as posted
28.6% (n=7)*1 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 2 Participants as posted
50% (n=2)*0.5 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 1 Participants as posted
50% (n=2)*0.5 mg/kg IV
NCT02573259 · Phase 1 · registry result, not featured evidence · converted to % from 1 Participants as posted
PFS 3 months300 mg SC
time to event · months
No placebo or comparator arm
RECIST v1.1
NCT02573259 · Phase 1 · registry result, not featured evidence
show 2 more results
3.7 months300 mg SC
RECIST v1.1
NCT02573259 · Phase 1 · registry result, not featured evidence
2.9 months300 mg SC
RECIST v1.1
NCT02573259 · Phase 1 · registry result, not featured evidence
Duration of Response NA months300 mg SC
time to event · months
No placebo or comparator arm
RECIST v1.1
NCT02573259 · Phase 1 · registry result, not featured evidence
show 2 more results
21.8 months300 mg SC
RECIST v1.1
NCT02573259 · Phase 1 · registry result, not featured evidence
13.9 months300 mg SC
RECIST v1.1
NCT02573259 · Phase 1 · registry result, not featured evidence
Time to Response 2.71 months300 mg SC
time to event · months
No placebo or comparator arm
NCT02573259 · Phase 1 · registry result, not featured evidence
show 1 more result
2.33 months300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
Time to Progression 3.7 months300 mg SC
time to event · months
No placebo or comparator arm
RECIST v1.1
NCT02573259 · Phase 1 · registry result, not featured evidence
show 1 more result
3.7 months300 mg SC
RECIST v1.1
NCT02573259 · Phase 1 · registry result, not featured evidence
Overall Survival 14.7 months300 mg SC
time to event · months
No placebo or comparator arm
NCT02573259 · Phase 1 · registry result, not featured evidence
show 1 more result
10.9 months300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
Overall Survival 0.773 Probability @ 26wk300 mg SC
absolute value · Probability
No placebo or comparator arm
NCT02573259 · Phase 1 · registry result, not featured evidence
show 5 more results
0.711 Probability @ 26wk300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
0.547 Probability @ 52wk300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
0.471 Probability @ 52wk300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
0.403 Probability @ 104wk300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence
0.286 Probability @ 104wk300 mg SC
NCT02573259 · Phase 1 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Penpulimab's landscape · Sasanlimab's landscape